BRISBANE, Calif., April 10 /PRNewswire/ -- BiPar Sciences, Inc. today announced the expansion of the clinical program for the company's lead product candidate, BSI-201, into glioblastoma multiforme ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback